The nuclear narrative has been hijacked by AI. From hyperscalers to data centers, the story has been simple: exploding compute demand needs baseload power. But Eli Lilly and Co (NYSE:LLY) just added a twist—and it has nothing to do with GPUs.
The drugmaker behind Prozac and Cialis is now exploring nuclear energy, signing a letter of intent with Indiana to support small modular reactors and advanced nuclear tech. The signal here isn’t about AI scale. It’s about something far more fundamental: industrial reliability.
Industrial Demand, Not AI Hype
Unlike data centers that can distribute workloads, pharmaceutical manufacturing doesn’t get that luxury. Production lines are tightly regulated, energy-intensive, and unforgiving to disruptions.
That’s where nuclear fits …
This post was originally published here
